To access this content, you must be a member. Visit the Plans page for details.
Armistice Capital down over 18% YTD, investors can’t redeem due to new terms
Armistice Capital, a biotech-focused firm, lost money in February, March and April. March’s 19% loss was the largest monthly loss [Read More]